胸腺肽在复治肺结核辅助治疗中的疗效观察  

Observation on the efficacy of thymic peptide for the assisted treatment of recurrent pulmonary tuberculosis

作　　者：王黎明[1] 

机构地区：[1]湖北省十堰市西苑医院,湖北十堰442000

出　　处：《中国当代医药》2011年第31期87-88,共2页China Modern Medicine

摘　　要：目的:探讨研究胸腺肽在复治肺结核辅助治疗中的疗效及其应用。方法:选取本院2009年1月～2011年3月复治肺结核149例的临床治疗情况,进行回溯式分析研究,患者被随机分为对照组与研究组并分别行基础治疗方案与附加胸腺肽的方案。结果:增加了胸腺肽进行辅助治疗的研究组其治愈率及总有效率分别为78.4%与93.3%,显著优于对照组。T淋巴细胞亚群变化对比发现,研究组在CD3、CD4、CD4/CD8比值方面治疗后3个月及治疗完成后较治疗前的检测值有显著提高。两组患者在临床副反应发生率与随访复发率方面差异无统计学意义(6.8%vs4.0%)。结论:对复治性肺结核治疗中使用免疫疗法改善机体的免疫功能,提高机体的抗菌能力,进而提高治疗效果。Objective：To discuss the efficacy of thymic peptide for assisted treatment of recurrent pulmonary tuberculosis.Methods：149 patients had been chosen and divided into two groups for routine curing and thymic peptide methods.Results：The treatment group＇s efficacy（93.3%） had statistical difference with control group.Compared with pretreatment,CD3,CD4 and CD4/8 after treatment for 3 months and at the end of treatment increased in treatment group.And there was no difference between two groups on side-effect and recurrence ratio.Conclusion：Thymic peptide for the treatment of recurrent pulmonary tuberculosis can improve sputum bacillus negative rates and focus absorption,and promote the recovery of immune function and increase the cure rate.

关 键 词：胸腺肽 复治性肺结核 T淋巴细胞 疗效 

分 类 号：R974[医药卫生—药品]